Yuhan Corporation

Cheol Hee Lim

Eun Kyung Kim

Hee Jae Tak

Hyok Jun Cho

Hyun Ho Choi

So Young Kim

Tae Dong Han

Sol Park

Na Ry Ha

Eui Chul Lee

Na Yeon Yang

Da Na Jeong

Woo Seob Shin

The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolones, tetrazolones, and imidazolones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same

The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

The present technology provides a process for selectively preparing an (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound by refluxing an (E/Z)-(2-(chloromethyl)-3-fluoroallyl)carbamate compound in an organic solvent, followed by crystallization by cooling.

Processes for preparing (E)-(2-(chloromethyl)-3-fluoroallyl) carbamate compounds

Growing community of inventors

Suwon-si, South Korea

Cheol Hee Lim